Contact
searchSearch
HMP Global

Atopic Dermatitis Topic Center

Featured Article

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Maria Asimopoulos
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
Headshot of Shawn Kwatra, MD, Johns Hopkins Itch Center, on a blue background underneath the PopHealth Perspectives logo.
Videos
Topical JAK Inhibitor Reduces Itch in Patients With Atopic Dermatitis
09/30/2022
Maria Asimopoulos
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, shares findings from a recent analysis of two phase 3 trials which investigated the efficacy and safety of a Janus kinase inhibitor for patients with moderate to severe atopic...
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, shares findings from a recent analysis of two phase 3 trials which investigated the efficacy and safety of a Janus kinase inhibitor for patients with moderate to severe atopic...
Shawn Kwatra, MD, FAAD,...
09/30/2022
First Report Managed Care
Headshot of Shawn Kwatra, MD, Johns Hopkins Itch Center, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Increased Market Competition May Impact Patients With Atopic Dermatitis
09/13/2022
Maria Asimopoulos
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, describes how the atopic dermatitis treatment paradigm has been changing amid increased market competition, as well as where the future of care may be headed.
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, describes how the atopic dermatitis treatment paradigm has been changing amid increased market competition, as well as where the future of care may be headed.
Shawn Kwatra, MD, FAAD,...
09/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
Headshot of Shawn Kwatra, MD, Johns Hopkins Itch Center, on a blue background underneath the PopHealth Perspectives logo.
Videos
Reviewing Unmet Need, Clinical Priorities for Patients With Atopic Dermatitis
08/31/2022
Maria Asimopoulos
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, identifies unmet need for patients with atopic dermatitis and shares what factors clinicians and patients prioritize when deciding on a treatment option. 
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, identifies unmet need for patients with atopic dermatitis and shares what factors clinicians and patients prioritize when deciding on a treatment option. 
Shawn Kwatra, MD, FAAD,...
08/31/2022
First Report Managed Care

Newsfeed

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
Correlation Between Atopic Dermatitis, Neuropsychiatric Comorbidities in Pediatric Populations
08/26/2022
Edan Stanley
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
Acupuncture Might Reduce Itching in Patients With Atopic Dermatitis
07/29/2022
Maria Asimopoulos
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
JAK1 Inhibitor Improves Atopic Dermatitis Symptoms, Even in Nonresponders
07/22/2022
Jolynn Tumolo
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care
News
FDA Issues Final Guidance on Biosimilar Prior Approval Supplements
09/10/2025
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug...
09/10/2025
First Report Managed Care
News
High Health Care Burden Among People with Hemophilia A Experiencing Bleeding or Joint Complications
09/10/2025
Juliet Gallagher
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows...
09/10/2025
First Report Managed Care
News
Confronting the HIV Epidemic: Addressing Gaps in Access, Adherence, and Equity
09/02/2025
Juliet Gallagher
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference,...
09/02/2025
First Report Managed Care
News
Industry Payments and Their Role in MS Drug Selection Among High-Volume Prescribers
08/28/2025
Juliet Gallagher
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study...
08/28/2025
First Report Managed Care
News
Medicare Advantage Plans See Double-Digit Satisfaction Drop as Medical Costs Soar
08/22/2025
Juliet Gallagher
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with...
08/22/2025
First Report Managed Care
News
Expanding Assertive Community Treatment to Transform Care for Complex Patients
08/20/2025
Lisa Kuhns, PhD, MD
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health...
08/20/2025
First Report Managed Care
News
AAM White Paper Spotlights Legislative Path to Breaking Biosimilar Patent Barriers
08/18/2025
Grace Taylor, MS, MA
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the...
08/18/2025
First Report Managed Care
News
FDA Expands Approval of Alhemo for Hemophilia A and B Without Inhibitors
08/14/2025
Juliet Gallagher
Novo Nordisk has announced the US Food and Drug Administration (FDA) approval of Alhemo (concizumab-mtci) for use as a once-daily subcutaneous prophylactic treatment in people 12 years and older with hemophilia A or B (HA/HB) without...
Novo Nordisk has announced the US Food and Drug Administration (FDA) approval of Alhemo (concizumab-mtci) for use as a once-daily subcutaneous prophylactic treatment in people 12 years and older with hemophilia A or B (HA/HB) without...
Novo Nordisk has announced the...
08/14/2025
First Report Managed Care
News
High-Efficacy Multiple Sclerosis Therapies Linked to Fewer Emergency Department Visits and Lower Risk
08/13/2025
Lisa Kuhns, PhD, MD
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying...
08/13/2025
First Report Managed Care
News
Roctavian Demonstrates Sustained Efficacy and Safety in Patients With Hemophilia A
08/04/2025
Grace Taylor, MS, MA
Five-year data from BioMarin’s phase 3 trial reveals Roctavian’s long-term efficacy, safety, and quality-of-life benefits for adults with severe hemophilia A.
Five-year data from BioMarin’s phase 3 trial reveals Roctavian’s long-term efficacy, safety, and quality-of-life benefits for adults with severe hemophilia A.
Five-year data from BioMarin’s...
08/04/2025
First Report Managed Care

Recent Content

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Maria Asimopoulos
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use